OncoZenge: Previous financing delays now resolved - Redeye

Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranche from its investment agreement with Yangtian. We are encouraged to see that the company has resolved the recent short-term financing uncertainty, restoring stability and maintaining momentum ahead of the upcoming phase III CTA milestone.

Länk till analysen i sin helhet: https://www.redeye.se/research/1149410/oncozenge-previous-financing-delays-now-resolved?utm_source=finwire&utm_medium=RSS